Literature DB >> 30542498

Sustained antidepressant action of the N-methyl-D-aspartate receptor antagonist MK-801 in a chronic unpredictable mild stress model.

Bang-Kun Yang1, Jun Qin2, Ying Nie3, Jin-Cao Chen1.   

Abstract

(5S,10R)-5-methyl-10,11-dihydro-5H-dibenzo(A,D)cyclohepten-5,10-imine hydrogen maleate (MK-801) is an N-methyl-D-aspartate non-competitive antagonist that possesses useful biological properties, including anticonvulsant and anesthetic activities. Studies have indicated the rapid antidepressant effects of MK-801 in animal models. However, there are no reports concerning a sustained antidepressant effect in the chronic unpredictable mild stress (CUMS) model. Furthermore, the antidepressant mechanism remains unclear. The aim of the present study was to examine the effects of MK-801 (0.1 mg/kg) and rapastinel (10 mg/kg) on depression-like behavior in CUMS mice and measure the protein expression of brain-derived neurotrophic factor (BDNF), α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (GluA1) and phosphorylated mammalian target of rapamycin (p-mTOR). In the tail suspension and forced swim tests, MK-801 significantly attenuated the increased immobility time in CUMS mice compared with the vehicle group. In the sucrose preference test, a single-dose injection of MK-801 significantly ameliorated the decreased sucrose preference in CUMS mice compared with the vehicle group. Western blot analyses indicated that MK-801 significantly attenuated the decreased BDNF, GluA1 and p-mTOR protein levels in the medial prefrontal cortex (mPFC), dentate gyrus (DG) and CA3 of the hippocampi of CUMS mice. Conversely, this compound had no effect on increased BDNF, GluA1 and p-mTOR protein levels in the nucleus accumbens of CUMS mice. Therefore, the present study revealed the sustained antidepressant effects of MK-801 in the CUMS model. Furthermore, synaptogenesis and neuronal regeneration in the prelimbic regions of mPFC, DG and CA3 of the hippocampus may be implicated as mechanisms that promote a sustained antidepressant response.

Entities:  

Keywords:  (5S,10R)-5-methyl-10,11-dihydro-5H-dibenzo(A,D)cyclohepten-5,10-imine hydrogen maleate; antidepressant; brain-derived neurotrophic factor; chronic unpredictable mild stress; rapastinel; synaptogenesis

Year:  2018        PMID: 30542498      PMCID: PMC6257797          DOI: 10.3892/etm.2018.6876

Source DB:  PubMed          Journal:  Exp Ther Med        ISSN: 1792-0981            Impact factor:   2.447


  35 in total

1.  Evidence for the involvement of NMDA receptors in the antidepressant-like effect of nicotine in mouse forced swimming and tail suspension tests.

Authors:  Arya Haj-Mirzaian; Nastaran Kordjazy; Arvin Haj-Mirzaian; Sattar Ostadhadi; Mehdi Ghasemi; Shayan Amiri; Mehrdad Faizi; AhmadReza Dehpour
Journal:  Psychopharmacology (Berl)       Date:  2015-07-15       Impact factor: 4.530

Review 2.  Antidepressant actions of ketamine: from molecular mechanisms to clinical practice.

Authors:  Lisa M Monteggia; Carlos Zarate
Journal:  Curr Opin Neurobiol       Date:  2015-01-03       Impact factor: 6.627

Review 3.  Region and state specific glutamate downregulation in major depressive disorder: a meta-analysis of (1)H-MRS findings.

Authors:  J J Luykx; K G Laban; M P van den Heuvel; M P M Boks; R C W Mandl; R S Kahn; S C Bakker
Journal:  Neurosci Biobehav Rev       Date:  2011-06-06       Impact factor: 8.989

4.  Comparison of ketamine, 7,8-dihydroxyflavone, and ANA-12 antidepressant effects in the social defeat stress model of depression.

Authors:  Ji-chun Zhang; Wei Yao; Chao Dong; Chun Yang; Qian Ren; Min Ma; Mei Han; Kenji Hashimoto
Journal:  Psychopharmacology (Berl)       Date:  2015-09-04       Impact factor: 4.530

5.  Synaptic plasticity and depression: new insights from stress and rapid-acting antidepressants.

Authors:  Ronald S Duman; George K Aghajanian; Gerard Sanacora; John H Krystal
Journal:  Nat Med       Date:  2016-03       Impact factor: 53.440

6.  An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-D-aspartate antagonist, CP-101,606, in patients with treatment-refractory major depressive disorder.

Authors:  Sheldon H Preskorn; Bryan Baker; Sheela Kolluri; Frank S Menniti; Michael Krams; Jaren W Landen
Journal:  J Clin Psychopharmacol       Date:  2008-12       Impact factor: 3.153

7.  GLYX-13, a NMDA receptor glycine-site functional partial agonist, induces antidepressant-like effects without ketamine-like side effects.

Authors:  Jeffrey Burgdorf; Xiao-lei Zhang; Katherine L Nicholson; Robert L Balster; J David Leander; Patric K Stanton; Amanda L Gross; Roger A Kroes; Joseph R Moskal
Journal:  Neuropsychopharmacology       Date:  2012-12-05       Impact factor: 7.853

8.  Regional differences in brain-derived neurotrophic factor levels and dendritic spine density confer resilience to inescapable stress.

Authors:  Chun Yang; Yukihiko Shirayama; Ji-Chun Zhang; Qian Ren; Kenji Hashimoto
Journal:  Int J Neuropsychopharmacol       Date:  2015-01-07       Impact factor: 5.176

Review 9.  Inflammatory biomarkers as differential predictors of antidepressant response.

Authors:  Kenji Hashimoto
Journal:  Int J Mol Sci       Date:  2015-04-08       Impact factor: 5.923

Review 10.  The Development of Rapastinel (Formerly GLYX-13); A Rapid Acting and Long Lasting Antidepressant.

Authors:  Joseph R Moskal; Jeffrey S Burgdorf; Patric K Stanton; Roger A Kroes; John F Disterhoft; Ronald M Burch; M Amin Khan
Journal:  Curr Neuropharmacol       Date:  2017       Impact factor: 7.363

View more
  2 in total

1.  Xiaoyaosan Exerts Antidepressant Effect by Downregulating RAGE Expression in Cingulate Gyrus of Depressive-Like Mice.

Authors:  Weixin Yan; Zhaoyang Dong; Di Zhao; Jun Li; Ting Zeng; Chan Mo; Lei Gao; Zhiping Lv
Journal:  Front Pharmacol       Date:  2021-09-07       Impact factor: 5.988

2.  Ketamine and Ro 25-6981 Reverse Behavioral Abnormalities in Rats Subjected to Dietary Zinc Restriction.

Authors:  Bartłomiej Pochwat; Helena Domin; Anna Rafało-Ulińska; Bernadeta Szewczyk; Gabriel Nowak
Journal:  Int J Mol Sci       Date:  2020-07-06       Impact factor: 5.923

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.